Written and maintained by CASRAI Editorial Board
Last updated
An Investigational Drug Service (IDS) — also called a research pharmacy, investigational pharmacy, or clinical trials pharmacy — is the pharmacy operation responsible for managing investigational product (IP) across a clinical trial’s full lifecycle: receipt from the sponsor, controlled storage, inventory accountability, randomization and blinding support, protocol-specific preparation and dispensing, and eventual reconciliation, return, or destruction of unused product. It exists as a distinct function — organizationally and regulatorily — from a routine hospital or retail pharmacy, which dispenses commercially approved medications against standard prescriptions with no sponsor accountability chain attached. See CASRAI’s dictionary entry on Research Pharmacy (Investigational Drug Service, IDS) for the operational definition; this guide covers the regulatory basis, day-to-day workflow, and staffing model in depth.
Why Every Clinical Trial Site Needs an IDS: The Regulatory Basis
An IDS is not an optional convenience — it exists to satisfy specific obligations that Good Clinical Practice places on both sponsors and investigators/institutions for how investigational product is handled:
- Sponsor obligations. ICH E6(R2), the internationally harmonized Good Clinical Practice guideline, assigns the sponsor responsibility for timely supply of investigational product and for written procedures covering its shipment, receipt, storage, dispensing, retrieval, and return or destruction (Section 5.14). See CASRAI’s breakdown of ICH E6(R2) Section 5 Sponsor Obligations for the full list.
- Investigator/institution accountability. The investigator or institution is accountable for investigational product at the trial site, and ICH E6 explicitly permits delegating the day-to-day handling of that product to a qualified pharmacist under the investigator’s supervision (Section 4.6) — the regulatory hook that makes a dedicated IDS pharmacist role possible in the first place.
- FDA recordkeeping and control requirements. Under 21 CFR 312.61, an investigator may only dispense investigational drug to subjects under investigation and may not supply it to any person not authorized to receive it. 21 CFR 312.62(a) requires the investigator to maintain adequate records of investigational drug disposition — dates, quantity, and use by each subject. 21 CFR 312.59 governs disposition of unused supplies at the end of a study: return to the sponsor or documented alternative disposal.
Together, these provisions mean an inspector or monitor can ask, at any point during a trial, “where is every unit of this drug, and can you prove it went where the protocol says it should have gone?” The IDS is the operational answer to that question.
Core IDS Functions Across the Investigational Product Lifecycle
Receipt and Storage
Investigational product typically arrives directly from the sponsor or its designated distributor, not through normal hospital pharmacy purchasing channels. The IDS verifies the shipment against accompanying documentation, inspects for shipping damage or temperature excursions (many IPs require refrigerated or frozen storage with continuous temperature monitoring and documented excursion-response procedures), and logs receipt into a protocol-specific inventory record before the product is released for use.
Inventory and Drug Accountability
Every unit received, dispensed, returned, or destroyed is tracked on a drug accountability log specific to that protocol and, often, that subject. This is the record a sponsor’s clinical research associate reviews at monitoring visits and that an FDA or IRB auditor reviews during an inspection — discrepancies between what the log says should be on the shelf and what is physically present are one of the most common clinical-trial audit findings.
Randomization and Blinding Support
In a blinded trial, someone has to know which treatment arm a subject was assigned to in order to prepare and dispense the correct product — without unblinding the study team assessing outcomes. IDS pharmacies commonly staff a designated unblinded pharmacist who accesses the randomization code, prepares and labels investigational product (and matching comparator or placebo) to preserve the blind, and remains walled off from subject-outcome assessment. See CASRAI’s guides on Blinding and Masking in Clinical Trials and RTSM (Randomization and Trial Supply Management) for how this integrates with broader trial supply systems, and Randomization Methods in Clinical Trials for the underlying statistical designs an IDS has to support operationally.
Preparation and Dispensing
Many investigational products — particularly injectable and oncology agents — require compounding, admixture, or dose calculation specific to a subject’s protocol-defined dose (which may be weight- or body-surface-area-based and may change between cycles). The IDS pharmacist prepares and dispenses against a protocol-specific order, not a standard formulary order, and verifies the dose against the protocol before release.
Return, Reconciliation, and Destruction
At the end of a subject’s participation, or the end of the study, unused product must be reconciled against the accountability log and either returned to the sponsor or destroyed according to a documented, often witnessed, procedure — the disposition requirement under 21 CFR 312.59. This closes the chain-of-custody loop the IDS has maintained since the product first arrived on site.
Who Staffs an Investigational Drug Service
Answering “what does an investigational drug service pharmacist actually do” in practice, the core roles are:
- Investigational drug pharmacist (IDS pharmacist). A licensed pharmacist with specific training in GCP, protocol interpretation, and clinical-trial drug handling — distinct from, though sometimes concurrent with, staff pharmacist duties in a routine hospital pharmacy. Responsibilities span protocol review before activation, accountability-log maintenance, dispensing, and serving as the site’s point of contact for sponsor drug-supply questions.
- IDS pharmacy technicians. Support inventory management, receipt logging, and preparation under pharmacist supervision, particularly at high-volume academic medical center IDS operations running many concurrent protocols.
- Unblinded pharmacist. A separately designated role (may be the same individual as the IDS pharmacist on a different protocol, but never on the same blinded protocol they are also assessing) responsible for randomization-code access and blinded product preparation, as described above.
- Principal investigator and delegated study staff. The PI retains ultimate accountability for investigational product at the site even where handling is delegated to the IDS; that delegation should be documented on the study’s Delegation of Authority (DoA) Log alongside every other delegated study task.
Where an IDS Sits Organizationally
Larger academic medical centers running high volumes of concurrent clinical trials commonly operate a centralized IDS as a distinct unit within the hospital or health-system pharmacy department, serving investigators across multiple departments and therapeutic areas rather than being built separately per study or per PI. Smaller sites and standalone research clinics may instead contract IDS functions to a health-system partner pharmacy, use a third-party investigational pharmacy service, or build a scaled-down version of the same accountability infrastructure in-house — the regulatory obligations under ICH E6 and 21 CFR Part 312 apply regardless of which organizational model a site uses.
IDS vs. Routine Hospital or Retail Pharmacy
| Dimension | Investigational Drug Service | Routine hospital/retail pharmacy |
|---|---|---|
| Product source | Sponsor or sponsor-designated distributor, protocol-specific | Standard wholesale/distributor purchasing |
| Regulatory approval status of product | Investigational — not yet approved, or approved product used outside its labeled indication under a protocol | FDA- or equivalent regulator-approved for the dispensed indication |
| Dispensing authority | Protocol-specific order, subject to accountability logging | Prescriber’s standard prescription |
| Accountability requirement | Unit-level chain of custody, sponsor and regulator auditable | Standard pharmacy dispensing records |
| Blinding considerations | May require a designated unblinded pharmacist role | Not applicable |
| End-of-study disposition | Formal return/destruction reconciliation (21 CFR 312.59) | Not applicable |
Professional Guidance and Standards
The American Society of Health-System Pharmacists (ASHP) maintains a dedicated Investigational Drug Services resource area and publishes ASHP Guidelines for the Management of Investigational Drug Products, covering staffing, storage, and accountability practice in detail. The Hematology/Oncology Pharmacy Association (HOPA) publishes complementary best-practice standards specific to investigational drug handling in oncology trials, where dosing complexity and blinding requirements are often greatest. Sites building or auditing an IDS program typically reference both alongside ICH E6 and applicable FDA regulations.
Related Pathways an IDS Often Also Supports
Because an IDS already has the infrastructure for handling product outside normal pharmacy channels, it is frequently the operational unit involved when a treating physician pursues expanded access (compassionate use) for a specific patient, or when a request falls under the Right to Try Act pathway. Both routes involve investigational product outside the standard trial-enrollment path, and both require the same kind of accountable receipt, storage, and dispensing infrastructure an IDS already maintains for its enrolled-trial work.
Frequently Asked Questions
What is an Investigational Drug Service?
An Investigational Drug Service (IDS) is the pharmacy function within a hospital or research institution responsible for receiving, storing, tracking, preparing, dispensing, and ultimately reconciling or returning investigational product used in clinical trials. It is also called a research pharmacy, investigational pharmacy, or clinical trials pharmacy.
What does an investigational drug service pharmacist do?
An IDS pharmacist reviews trial protocols before activation, maintains drug accountability logs, receives and stores investigational product under protocol-specified conditions, prepares and dispenses product against protocol-specific (not standard prescription) orders, may serve as the designated unblinded pharmacist on blinded studies, and manages end-of-study return or destruction. They are typically the site’s primary point of contact for sponsor and monitor questions about drug supply.
Is an IDS the same as a research pharmacy?
Yes. “Investigational Drug Service,” “research pharmacy,” “investigational pharmacy,” and “clinical trials pharmacy” are used interchangeably across institutions and the professional literature to describe the same function.
Does every clinical trial site need a dedicated IDS?
Every site handling investigational product needs the accountability infrastructure ICH E6 and 21 CFR Part 312 require — but not every site needs a large, standalone IDS unit to provide it. High-volume academic medical centers typically operate a centralized IDS serving many concurrent protocols; smaller or standalone research sites may contract the function to a partner pharmacy or a third-party investigational pharmacy service while still meeting the same regulatory obligations.
What happens to unused investigational drug at the end of a study?
Unused investigational product must be reconciled against the site’s drug accountability log and then returned to the sponsor or destroyed through a documented, often witnessed, disposal procedure, per 21 CFR 312.59. This final reconciliation closes the chain-of-custody record the IDS has maintained since the product first arrived on site.
